Circulating Adipokines and Associations With Incident Cardiovascular Disease in Rheumatoid Arthritis
Lydia E Federico1, Tate M Johnson2, Bryant R England2
1University of Pennsylvania, Philadelphia.
Insights
High levels of adiponectin and leptin are linked to increased cardiovascular disease (CVD) death in rheumatoid arthritis (RA) patients, especially nonobese individuals. Fibroblast growth factor 21 (FGF-21) showed a protective association with coronary artery disease (CAD).
Area of Science:
- Rheumatology
- Cardiology
- Endocrinology
Background:
- Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular disease (CVD).
- Adipokines, such as adiponectin, leptin, and fibroblast growth factor 21 (FGF-21), play roles in inflammation and metabolism, potentially influencing CVD risk.
- Understanding the specific roles of these adipokines in RA-related CVD is crucial for risk stratification.
Purpose of the Study:
- To investigate the association between circulating levels of adiponectin, leptin, and FGF-21 and the incidence of cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA).
Main Methods:
- Serum samples from RA patients were analyzed for adipokine levels (adiponectin, leptin, FGF-21).
- Incident CVD events, including coronary artery disease (CAD), stroke, heart failure (HF) hospitalization, venous thromboembolism, and CVD-related deaths, were tracked.
- Multivariable Cox proportional hazards models were used to assess the relationship between adipokine concentrations and CVD incidence, with adjustments for relevant covariates.
Main Results:
- High adiponectin levels were independently associated with increased risk of HF hospitalization (HR 1.39) and CVD-related death (HR 1.49).
- High leptin levels were independently associated with an increased risk of CVD-related death (HR 1.44).
- High FGF-21 levels were independently associated with a reduced risk of CAD (HR 0.75).
- Associations between high adiponectin and leptin with CVD-related death were more pronounced in nonobese RA patients.
Conclusions:
- Circulating adipokines, specifically adiponectin and leptin, are associated with adverse cardiovascular outcomes, including heart failure hospitalization and CVD-related death, in patients with RA.
- The observed associations were stronger in nonobese individuals, suggesting a complex interplay between adipokines, body composition, and CVD risk in RA.
- These adipokines may serve as potential biomarkers for predicting CVD risk in RA patients, warranting further investigation to augment current risk assessment tools.
Objective:
To assess whether circulating levels of adiponectin, leptin, and fibroblast growth factor 21 (FGF-21) are associated with incident cardiovascular disease (CVD) in rheumatoid arthritis (RA).
Methods:
Adipokines were measured using banked enrollment serum from patients with RA and dichotomized above/below the median value. Incident CVD events (coronary artery disease [CAD], stroke, heart failure [HF] hospitalization, venous thromboembolism, CVD-related deaths) were identified using administrative data and the National Death Index. Covariates were derived from medical record, biorepository, and registry databases. Multivariable Cox models were generated to quantify associations between adipokine concentrations and CVD incidence. Five-year incidence rates were predicted.
Results:
Among 2,598 participants, 639 (25%) had at least 1 CVD event over 19,585 patient-years of follow-up. High adiponectin levels were independently associated with HF hospitalization (hazard ratio [HR] 1.39 [95% confidence interval (95% CI) 1.07-1.79], P = 0.01) and CVD-related death (HR 1.49 [95% CI 1.16-1.92], P = 0.002) but not with other CVD events. High leptin was independently associated with CVD-related death (HR 1.44 [95% CI 1.05-1.97], P = 0.02). High FGF-21 levels were independently associated with lower rates of CAD (HR 0.75 [95% CI 0.58-0.97], P = 0.03). In subgroup analyses, associations between high adiponectin and leptin levels with CVD-related death were driven by strong associations in nonobese patients.
Conclusion:
Adipokines are associated with HF hospitalization and CVD-related death in patients with RA, with stronger associations in nonobese participants. These findings suggest that adipokines effectively predict clinically important outcomes in RA perhaps through an association with body composition and metabolic health. Further study is needed to determine whether adipokine measures might augment existing tools to identify RA patients at increased risk of CVD.
Related Concept Videos
The JAK-STAT Signaling Pathway
Rheumatic Heart Disease I: Introduction
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Coronary Artery Disease I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...


